China Pharma Statistics
Share Statistics
China Pharma has 19.25M shares outstanding. The number of shares has increased by 68.95% in one year.
| Shares Outstanding | 19.25M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 12.18% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 9.38M |
| Failed to Deliver (FTD) Shares | 6.10K |
| FTD / Avg. Volume | 0.73% |
Short Selling Information
The latest short interest is 93.60K, so 0.49% of the outstanding shares have been sold short.
| Short Interest | 93.60K |
| Short % of Shares Out | 0.49% |
| Short % of Float | 1% |
| Short Ratio (days to cover) | 0.22 |
Valuation Ratios
The PE ratio is -0.66 and the forward PE ratio is null.
| PE Ratio | -0.66 |
| Forward PE | null |
| PS Ratio | 0.29 |
| Forward PS | null |
| PB Ratio | 0.27 |
| P/FCF Ratio | -2.88 |
| PEG Ratio | n/a |
Enterprise Valuation
China Pharma Inc. has an Enterprise Value (EV) of 5.26M.
| EV / Earnings | -1.71 |
| EV / Sales | 0.75 |
| EV / EBITDA | 623.19 |
| EV / EBIT | -1.91 |
| EV / FCF | -7.39 |
Financial Position
The company has a current ratio of 0.88, with a Debt / Equity ratio of 0.61.
| Current Ratio | 0.88 |
| Quick Ratio | 0.33 |
| Debt / Equity | 0.61 |
| Total Debt / Capitalization | 37.73 |
| Cash Flow / Debt | -0.15 |
| Interest Coverage | -8.25 |
Financial Efficiency
Return on equity (ROE) is -0.41% and return on capital (ROIC) is -22.76%.
| Return on Equity (ROE) | -0.41% |
| Return on Assets (ROA) | -0.19% |
| Return on Capital (ROIC) | -22.76% |
| Revenue Per Employee | 30.35K |
| Profits Per Employee | -13.33K |
| Employee Count | 231 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 1.95 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -57.94% in the last 52 weeks. The beta is 0.71, so China Pharma 's price volatility has been higher than the market average.
| Beta | 0.71 |
| 52-Week Price Change | -57.94% |
| 50-Day Moving Average | 0.21 |
| 200-Day Moving Average | 0.25 |
| Relative Strength Index (RSI) | 47.4 |
| Average Volume (20 Days) | 838.20K |
Income Statement
In the last 12 months, China Pharma had revenue of 7.01M and earned -3.08M in profits. Earnings per share was -0.91.
| Revenue | 7.01M |
| Gross Profit | -281.08K |
| Operating Income | -2.75M |
| Net Income | -3.08M |
| EBITDA | 8.44K |
| EBIT | -2.75M |
| Earnings Per Share (EPS) | -0.91 |
Balance Sheet
The company has 1.42M in cash and 4.63M in debt, giving a net cash position of -3.21M.
| Cash & Cash Equivalents | 1.42M |
| Total Debt | 4.63M |
| Net Cash | -3.21M |
| Retained Earnings | -39.29M |
| Total Assets | 13.47M |
| Working Capital | -1.02M |
Cash Flow
In the last 12 months, operating cash flow was -699.69K and capital expenditures -11.52K, giving a free cash flow of -711.20K.
| Operating Cash Flow | -699.69K |
| Capital Expenditures | -11.52K |
| Free Cash Flow | -711.20K |
| FCF Per Share | -0.21 |
Margins
Gross margin is -4.01%, with operating and profit margins of -39.25% and -43.91%.
| Gross Margin | -4.01% |
| Operating Margin | -39.25% |
| Pretax Margin | -43.91% |
| Profit Margin | -43.91% |
| EBITDA Margin | 0.12% |
| EBIT Margin | -39.25% |
| FCF Margin | -10.14% |
Dividends & Yields
CPHI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -455% |
| FCF Yield | -18.41% |
Analyst Forecast
Currently there are no analyst rating for CPHI.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Mar 6, 2024. It was a backward split with a ratio of 1:5.
| Last Split Date | Mar 6, 2024 |
| Split Type | backward |
| Split Ratio | 1:5 |
Scores
| Altman Z-Score | -4.85 |
| Piotroski F-Score | 1 |